Log in

NYSE:HAE - Haemonetics Stock Price, Forecast & News

$107.45
-2.61 (-2.37 %)
(As of 01/26/2020 04:00 PM ET)
Today's Range
$106.87
Now: $107.45
$110.13
50-Day Range
$107.45
MA: $116.16
$121.26
52-Week Range
$80.24
Now: $107.45
$140.36
Volume555,176 shs
Average Volume362,669 shs
Market Capitalization$5.45 billion
P/E Ratio82.65
Dividend YieldN/A
Beta0.74
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP40502410
Phone781-848-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.58 million
Cash Flow$4.52 per share
Book Value$13.09 per share

Profitability

Net Income$55.02 million

Miscellaneous

Employees3,216
Market Cap$5.45 billion
Next Earnings Date2/4/2020 (Confirmed)
OptionableOptionable

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.


Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How will Haemonetics' stock buyback program work?

Haemonetics declared that its Board of Directors has initiated a share buyback program on Tuesday, February 6th 2018, which permits the company to repurchase $260,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) announced its quarterly earnings results on Friday, November, 1st. The medical instruments supplier reported $0.87 EPS for the quarter, beating the consensus estimate of $0.72 by $0.15. The medical instruments supplier earned $252.57 million during the quarter, compared to the consensus estimate of $249.77 million. Haemonetics had a net margin of 6.90% and a return on equity of 24.59%. View Haemonetics' Earnings History.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Haemonetics.

How can I listen to Haemonetics' earnings call?

Haemonetics will be holding an earnings conference call on Tuesday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY20 earnings guidance on Friday, November, 1st. The company provided earnings per share (EPS) guidance of $3.10-3.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.09. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.01 billion.

What price target have analysts set for HAE?

6 Wall Street analysts have issued 1-year price objectives for Haemonetics' stock. Their forecasts range from $138.00 to $148.00. On average, they expect Haemonetics' share price to reach $142.83 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price. View Analyst Price Targets for Haemonetics.

What is the consensus analysts' recommendation for Haemonetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

Has Haemonetics been receiving favorable news coverage?

News articles about HAE stock have been trending extremely negative on Sunday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Haemonetics earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Haemonetics.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Apache (APA), Zoetis (ZTS), NVIDIA (NVDA), Pfizer (PFE), Micron Technology (MU), Nexstar Media Group (NXST) and Citigroup (C).

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:
  • Mr. Christopher Simon, CEO, Pres & Director (Age 55)
  • Mr. William P. Burke, CFO & Exec. VP
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec.
  • Ms. Jacqueline D. Scanlan, Sr. VP of Global HR
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 42)

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Boston Trust Walden Corp (0.24%), Columbus Circle Investors (0.24%), New York State Teachers Retirement System (0.17%), Assenagon Asset Management S.A. (0.06%), State of Michigan Retirement System (0.03%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

Which major investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Nisa Investment Advisors LLC, State of Alaska Department of Revenue, New York State Teachers Retirement System, Campbell & CO Investment Adviser LLC and Cardinal Capital Management. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

Which major investors are buying Haemonetics stock?

HAE stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Columbus Circle Investors, Boston Trust Walden Corp, Eqis Capital Management Inc., Sciencast Management LP, HBW Advisory Services LLC, State of Michigan Retirement System and Louisiana State Employees Retirement System. View Insider Buying and Selling for Haemonetics.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $107.45.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $5.45 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

What is Haemonetics' official website?

The official website for Haemonetics is http://www.haemonetics.com/.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (NYSE HAE)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  395 (Vote Underperform)
Total Votes:  692
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Featured Article: Municipal Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel